Parexel Appoints Scott Smith, M.D., Ph.D. as New Head of Hematology
Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Scott Smith, M.D., Ph.D. as Senior Vice President, Global Therapeutic Area Head of Hematology. In this role, Dr. Smith will lead Parexel’s Hematology therapeutic area and global team within our Oncology Center of Excellence in the development of new treatments for malignant hematology diseases as well as in the development of new therapies to treat non-malignant hematology diseases.
“Cancer is expected to continue being a significant healthcare burden, making our medical expertise in this area even more critical to providing the support our customers and patients need to bring new, important therapies to market,” said Amy McKee, M.D., Chief Medical Officer and Head, Oncology Center of Excellence. “Dr. Scott’s extensive knowledge in hematology, expertise in directing oncology clinical trials and experience practicing medicine make him an ideal choice to lead our hematology therapeutic area as we continue to strengthen Parexel’s leadership position in this critical therapeutic area.”
Dr. Smith is a licensed physician and surgeon with more than 26 years of medical experience at the Loyola University Medical Center in Illinois. Prior to joining Parexel, Scott held several positions of increasing responsibility at Loyola Medicine’s Cardinal Bernardin Cancer Center, including Director, Cancer Clinical Trials Office; Director, Bone Marrow Transplant Program; Section Chief of Hematology; and Associate Director, Clinical Research.
In these roles, Dr. Smith made significant contributions to increase the number of lymphoma clinical trials – helping to bring a new drug to market to treat relapsed Hodgkin’s lymphoma while working to change the standard of care for patients. Dr. Smith’s experience also includes serving as Executive Officer for the Alliance of Clinical Trials in Oncology in Chicago, leading the group’s hematology research portfolio. He is actively involved in the industry and serves on the Lymphoma Committee and Bone Marrow and Stem Cell Transplant Committee at the SWOG Cancer Research Network along with the Protocol Review Committee at Loyola University Chicago.
“At Parexel, we are passionate about achieving better outcomes for patients,” added Peyton Howell, Chief Operating and Growth Officer. “By widening our bench of medical experts and industry thought leaders, we continue to make progress on delivering the best possible treatment options to patients worldwide.”
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more